⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425138 | 1.00 | — | — | |
| SCHEMBL4012197 | 1.00 | CYP1A2 (0.58) | — | |
| Bromide SCHEMBL28346962 | 0.98 | CYP1A2 (0.56) | — | |
| Hydrochloric Acid SCHEMBL245336 | 0.98 | — | — | |
| Ammonia Solution, Strong SCHEMBL2404843 | 0.98 | — | — | |
| Iodide SCHEMBL3629513 | 0.98 | — | — | |
| Bromide SCHEMBL146199 | 0.98 | — | — | |
| Bromide SCHEMBL30101770 | 0.98 | — | — | |
| Bromide SCHEMBL1259499 | 0.95 | — | — | |
| Bromide SCHEMBL28258886 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1392 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250362307-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | LIAO JUNG CHI (TW) | 2025-11-27 | — | — | US | claimed |
| EP-4473309-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | Syncell (Taiwan) Inc. (TW) | 2024-12-11 | — | — | EP | claimed |
| CN-119013558-A | Photoactivated antibody conjugates | 新析生物科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023196986-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | Syncell (Taiwan) Inc. (TW) | 2023-10-12 | — | — | WO | claimed |
| US-11046721-B2 | Ruthenium-based photolinkers and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-06-29 | — | — | US | claimed |
| US-20170260221-A1 | Ruthenium-Based Photolinkers and Methods of Use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-09-14 | — | — | US | claimed |
| WO-2016022526-A1 | RUTHENIUM-BASED PHOTOLINKERS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-11 | — | — | WO | claimed |
| EP-1781629-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2015-07-29 | — | — | EP | claimed |
| EP-2216372-B1 | Compounds for preventing Ghost odour | THOR GMBH (DE) | 2014-06-04 | — | — | EP | claimed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | claimed |
| EP-1979334-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2011-06-22 | — | — | EP | claimed |
| US-7943646-B2 | Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-05-17 | — | — | US | claimed |
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO. LTD. (KR) | 2010-09-30 | — | — | US | claimed |
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL IND. CO., LTD. | 2010-09-23 | — | — | US | claimed |
| EP-2170878-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING THE SAME | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2010-04-07 | — | — | EP | claimed |
| US-20090054642-A1 | NOVEL BENZAMIDINE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONGWHA PHARMACEUTICAL IND. CO., LTD. (KR) | 2009-02-26 | — | — | US | claimed |
| WO-2009017346-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2009-02-05 | — | — | WO | claimed |
| EP-1979334-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong Wha Pharmaceutical. Ind. Co., Ltd. (KR) | 2008-10-15 | — | — | EP | claimed |
| WO-2007089101-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL IND.CO., LTD. (KR) | 2007-08-09 | — | — | WO | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12624022-B2 | Heterocyclic immunomodulators as PDL1 checkpoint inhibitor | Janssen Sciences Ireland Unlimited Company (IE) | 2026-05-12 | — | — | US | disclosed |
| US-12617785-B2 | Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss | THE ROCKEFELLER UNIVERSITY (US) | 2026-05-05 | — | — | US | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12570860-B2 | Two-component treatment agent, treatment method for making metal surface antibacterial and antibacterial treatment agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250362307-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | LIAO JUNG CHI (TW) | 2025-11-27 | — | — | US | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-4630423-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12324799-B2 | Methods and uses of colchicine derivatives | ALBERTA HEALTH SERVICES (CA) | 2025-06-10 | — | — | US | disclosed |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-3971187-B1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119923385-A | Inhibitors of RNA helicase DHX9 and uses thereof | 埃克森特治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543859-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | Flindr Therapeutics B.V. (NL) | 2025-04-30 | — | — | EP | disclosed |
| US-20250129077-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2025-04-24 | — | — | US | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4100008-B1 | PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | UNIV ROCKEFELLER (US) | 2025-04-02 | — | — | EP | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| CN-119613328-A | NAMPT inhibitor, composition, preparation method and application | 南华大学附属第一医院 | 2025-03-14 | — | — | CN | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| CN-119528912-A | Pyrrole [2,3-d ] pyrimidine compound or pharmaceutically acceptable salt thereof and application thereof | 南方医科大学 | 2025-02-28 | — | — | CN | disclosed |
| EP-4512816-A2 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-119403787-A | 3- (Sulfonyl or iminosulfonyl) prop-2-en-1-yl ] -2-oxo-1, 2-dihydropyridine-3-carboxamide derivatives | 福临德治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119371420-A | Naphthyridones derivative and preparation method thereof | 上海翰森生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-4219463-B1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119306721-A | Cuppyridine-pyrene tetrasulfonic acid tetrasodium salt supermolecule nano sensor and application thereof to heparin sodium content detection | 天津师范大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4479138-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| EP-4473309-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | Syncell (Taiwan) Inc. (TW) | 2024-12-11 | — | — | EP | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024240155-A1 | DIKETONE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州大学 | 2024-11-28 | — | — | WO | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119013558-A | Photoactivated antibody conjugates | 新析生物科技股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994100-A | Diketone compound and preparation method and application thereof | 苏州大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| CN-118834183-A | (Z) -3-butenyl phthalide 5-or 7-position derivative, preparation method, application and pharmaceutical composition thereof | 中国医学科学院药物研究所 | 2024-10-25 | — | — | CN | disclosed |
| CN-118638053-B | Synthesis method of 8-chloro-5, 6-dihydro-11H-benzo [5,6] cyclohepta- [1,2-b ] pyridin-11-one | 浙江弘盛药业有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118638053-B | Synthesis method of 8-chloro-5, 6-dihydro-11H-benzo [5,6] cyclohepta- [1,2-b ] pyridin-11-one | 浙江弘盛药业有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4438123-A2 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| CN-118652256-A | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2024-09-17 | — | — | CN | disclosed |
| CN-118638053-A | Synthesis method of 8-chloro-5, 6-dihydro-11H-benzo [5,6] cyclohepta- [1,2-b ] pyridin-11-one | 浙江弘盛药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118638053-A | Synthesis method of 8-chloro-5, 6-dihydro-11H-benzo [5,6] cyclohepta- [1,2-b ] pyridin-11-one | 浙江弘盛药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-113966329-B | Heterocyclic immunomodulators as PDL1 checkpoint inhibitors | 爱尔兰詹森科学公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12054496-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024152986-A1 | HETEROARYL AMINO COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118359535-A | Synthesis method of N-tert-butoxycarbonyl-3-pyridyl-D/L-alanine | 武汉理工大学 | 2024-07-19 | — | — | CN | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024140968-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-4310087-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4305034-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-114901646-B | Benzotriazine bisoxides and pharmaceutical compositions thereof | 浙江瑞臻医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240174612-A1 | BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2024-05-30 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| US-20240166627-A1 | Terpyridinedione compound or salt thereof, and preparation method and application thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| US-20240166678-A1 | Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-05-23 | — | — | US | disclosed |
| CN-110234628-B | Process for preparing methoxymethyl pyridine dicarboxylic acid ester | 阿达玛阿甘有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024102306-A1 | HIGHLY WATER SOLUBLE SCHIFF BASE PRODRUGS OF BENZALDEHYDE ALLOSTERIC MODULATORS | ILLEXCOR HOLDINGS, LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102304-A1 | BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240158374-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150388-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | CORNELL UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114929707-B | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117820214-A | Process for preparing methoxymethyl pyridine dicarboxylic acid ester | 阿达玛阿甘有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240109843-A1 | BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE | KING ABDULAZIZ UNIVERSITY (SA) | 2024-04-04 | — | — | US | disclosed |
| US-11939330-B1 | Pyrido[3,4-b]indole-6-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2024-03-26 | — | — | US | disclosed |
| CN-117756780-A | Efficient and clean treatment method for synthesizing imazamox | 江苏扬农化工股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-113766914-B | Pentaneamidine analogues and uses thereof | 美商奥润沙公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114904474-B | Device and method for reacting diethyl 5-bromomethylpyridine-2, 3-dicarboxylic acid | 内蒙古新农基科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117460743-A | Small molecule VE-PTP inhibitors | 曼宁研究公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4310087-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308562-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4305034-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-11873312-B2 | Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117402183-A | Boron-containing compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117343081-A | MAT2A inhibitor, pharmaceutical composition and application thereof | 南京正大天晴制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| WO-2023249490-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | IMMAGENE B.V. (NL) | 2023-12-28 | — | — | WO | disclosed |
| EP-3802550-B1 | NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING | INST NAT SANTE RECH MED (FR) | 2023-12-27 | — | — | EP | disclosed |
| US-11851430-B1 | Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2023-12-26 | — | — | US | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845771-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | GLYCOMIMETICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-116648244-B | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4288433-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-4277897-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| CN-117088885-A | Triazolopyridazine compound and application thereof | 上海赛默罗生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| CN-116981665-A | Novel compounds | 思瑞万斯公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116964044-A | Acetamido-phenyltetrazole derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230339972-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| WO-2023196875-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196986-A1 | PHOTOACTIVE ANTIBODY CONJUGATE | Syncell (Taiwan) Inc. (TW) | 2023-10-12 | — | — | WO | disclosed |
| US-11767333-B2 | Benzimidamides compounds comprising an oxaborinin ring | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-09-26 | — | — | US | disclosed |
| CN-116802182-A | Pyrazolopyridine derivatives and uses thereof | 诺华股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-3003322-B1 | MANNOSE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY ST LOUIS (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| CN-116710442-A | Compounds, compositions and methods for treating disorders | 成都安泰康赛生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116648244-A | Terpyridyl dione compound or salt thereof, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4225747-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-113929618-B | Oxo-pyridine amide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023150619-A2 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-08-10 | — | — | WO | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219463-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-115448921-B | Imidazolidine pyrimidinone compounds and use thereof in treatment of HsClpP mediated diseases | 四川大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-116478154-A | Quinuclidine derivative and preparation method and application thereof | 北京大学宁波海洋药物研究院 | 2023-07-25 | — | — | CN | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| EP-3980413-B1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3980413-B1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-07-19 | — | — | EP | disclosed |
| CN-116444515-A | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023119320-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192718-A1 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | NIROGY THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192718-A1 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | NIROGY THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023104148-A1 | SMALL MOLECULE PROBE BINDING TO α-SYNUCLEIN AGGREGATE AND APPLICATION THEREOF | 复旦大学 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-116251199-A | Small molecule probes that bind to alpha-synuclein aggregates and uses thereof | 复旦大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-116261557-A | Cyclic cyanoketene derivatives as KEAP1 modulators | 默沙东有限责任公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-114127053-B | Substituted pyrazine compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| CN-116217603-A | New compounds | 国家医疗保健研究所 | 2023-06-06 | — | — | CN | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| CN-111051309-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4182299-A2 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | Merck Sharp & Dohme LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-116143752-A | Compound containing heterocycloalkyl or cycloalkyl and medical application thereof | 正大天晴药业集团股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230137893-A1 | PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230137893-A1 | PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| EP-4164690-A1 | SMALL MOLECULE VE-PTP INHIBITORS | Ripka, Amy (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115974897-A | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-113912586-B | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| CN-112236433-B | Novel compounds | 国家医疗保健研究所 | 2023-04-04 | — | — | CN | disclosed |
| CN-112608320-B | Piperidine compound and preparation method and medical application thereof | 中国药科大学 | 2023-03-17 | — | — | CN | disclosed |
| US-20230079833-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-11584755-B2 | Dihydrothieno[3,2-b]pyridine compounds | IDEAYA BIOSCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| CN-112368283-B | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023016535-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016535-A1 | TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2023015236-A2 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-115698020-A | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2023-02-03 | — | — | CN | disclosed |
| US-20230033327-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
| US-20220411377-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY | 2022-12-29 | — | — | US | disclosed |
| CN-218131813-U | 5-bromomethylpyridine-2,3-dicarboxylic acid diethyl ester reaction device | 内蒙古新农基科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-115515579-A | Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss | 洛克菲勒大学 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100008-A1 | PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | The Rockefeller University (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115448921-A | Imidazolidinone pyrimidone compounds and application thereof in treatment of HsClpP mediated diseases | 四川大学 | 2022-12-09 | — | — | CN | disclosed |
| EP-4097110-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | Oncodesign S.A. (FR) | 2022-12-07 | — | — | EP | disclosed |
| CN-110382463-B | HDAC6 selective inhibitor and preparation method and application thereof | 基石药业（苏州）有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113061125-B | Preparation method of imidazolidinone compound | 沈阳中化农药化工研发有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022195454-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
| US-20220265693-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | GLYCOMIMETICS, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220265691-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | GLYCOMIMETICS, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220267357-A1 | Novel Benzimidamides Compounds Comprising an Oxaborinin Ring | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2022-08-25 | — | — | US | disclosed |
| US-20220267615-A1 | TWO-COMPONENT TREATMENT AGENT, TREATMENT METHOD FOR MAKING METAL SURFACE ANTIBACTERIAL AND ANTIBACTERIAL TREATMENT AGENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| EP-3569592-B1 | HDAC6 SELECTIVE INHIBITORS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CSTONE PHARMACEUTICAL SUZHOU CO LTD (CN) | 2022-08-24 | — | — | EP | disclosed |
| CN-114929707-A | EED inhibitor and preparation method and application thereof | 上海科技大学 | 2022-08-19 | — | — | CN | disclosed |
| US-20220259201-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259186-A1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2022-08-18 | — | — | US | disclosed |
| CN-114901646-A | Benzotriazine double oxide and pharmaceutical composition thereof | 杭州瑞臻医药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022167819-A1 | NOVEL COMPOUNDS | Cerevance, Inc. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-20220233684-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2022-07-28 | — | — | US | disclosed |
| EP-3450436-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2022152097-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-07-21 | — | — | WO | disclosed |
| US-11390634-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-19 | — | — | US | disclosed |
| US-20220213112-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-4019515-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| US-11352372-B2 | Benzimidamides compounds comprising an oxaborinin ring | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-06-07 | — | — | US | disclosed |
| EP-4003367-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | GlycoMimetics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3997247-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | GlycoMimetics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | LES LABORATOIRES SERVIER (FR) | 2022-05-17 | — | — | US | disclosed |
| CN-111533721-B | Benzopyrone or quinolinone compounds and application thereof | 浙江大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-114401726-A | Use of E-selectin antagonists to improve survival of reconstituted bone marrow depleted hosts | 糖模拟物有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022076663-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3980413-A1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-13 | — | — | EP | disclosed |
| CN-108430994-B | Compounds, compositions and methods for modulating CFTR | 蛋白质平衡治疗股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220098198-A1 | SUBSTITUTED PURINES AS TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-20220089633-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3971187-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3958978-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GlycoMimetics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114127053-A | Substituted pyrazine compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-107406422-B | Pyrazole derivatives as sGC stimulators | 赛科理音医疗有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113999232-A | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113966329-A | Heterocyclic immunomodulators as PDL1 checkpoint inhibitors | 爱尔兰詹森科学公司 | 2022-01-21 | — | — | CN | disclosed |
| WO-2022013408-A2 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| CN-113929618-A | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113912586-A | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-109415384-B | Fused heterocyclic compound | 武田药品工业株式会社 | 2022-01-11 | — | — | CN | disclosed |
| US-11220510-B2 | Pyrrole tricyclic compounds as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021257754-A1 | SMALL MOLECULE VE-PTP INHIBITORS | RIPKA, AMY (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3197277-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113788815-A | Synthetic preparation method of nicotine intermediate | 成昌梅 | 2021-12-14 | — | — | CN | disclosed |
| EP-3486242-B1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| CN-108495850-B | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3911307-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | GlycoMimetics, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-110993798-B | Perovskite type solar cell based on synergistic post-treatment of multiple ammonium salts and preparation thereof | 北京大学 | 2021-11-19 | — | — | CN | disclosed |
| CN-107567455-B | Herbicidal compounds | 先正达参股股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-111187172-B | Nitrophenyl ether compound, preparation method thereof, pharmaceutical composition and application | 中国药科大学 | 2021-10-29 | — | — | CN | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3893936-A2 | METHODS OF TREATING HIV AND AIDS AND THE ELIMINATION OF LATENT RESERVOIRS OF HIV INFECTION USING SELECTIN, GALECTIN, AND SIGLEC ANTAGONISTS | GlycoMimetics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210317136-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-10-14 | — | — | US | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| CN-108883099-B | Thiazolidinone compounds and use thereof | 石全 | 2021-09-28 | — | — | CN | disclosed |
| US-20210292352-A1 | Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-23 | — | — | US | disclosed |
| US-11124617-B2 | Materials coated with calixarenes | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2021-09-21 | — | — | US | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| US-20210283092-A1 | METHODS AND USES OF COLCHICINE DERIVATIVES | ALBERTA HEALTH SERVICES (CA) | 2021-09-16 | — | — | US | disclosed |
| EP-3194382-B1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3194382-B1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210253604-A1 | Novel Benzimidamides Compounds Comprising an Oxaborinin Ring | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-08-19 | — | — | US | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| WO-2021158936-A1 | PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | THE ROCKEFELLER UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158936-A1 | PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | THE ROCKEFELLER UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| US-11084808-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| WO-2021152165-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2021-08-05 | — | — | WO | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3378861-B1 | ACRYLIC ACID DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20210221793-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2021143680-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| WO-2021143792-A1 | PIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-07-22 | — | — | WO | disclosed |
| US-11059824-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11046721-B2 | Ruthenium-based photolinkers and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210179592-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-17 | — | — | US | disclosed |
| US-11021502-B2 | Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-06-01 | — | — | US | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2021096314-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | 가천대학교 산학협력단 | 2021-05-20 | — | — | WO | disclosed |
| EP-3820573-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
| EP-3813821-A1 | METHODS AND USES OF COLCHICINE DERIVATIVES | Alberta Health Services (CA) | 2021-05-05 | — | — | EP | disclosed |
| EP-3814356-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-20210122776-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-29 | — | — | US | disclosed |
| WO-2021081528-A1 | SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2021-04-29 | — | — | WO | disclosed |
| CN-112694472-A | BuChE-IDO1 inhibitor, preparation method and application thereof | 西南大学 | 2021-04-23 | — | — | CN | disclosed |
| US-20210115067-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | disclosed |
| US-10981934-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3801538-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3802550-A1 | NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2021-04-14 | — | — | EP | disclosed |
| CN-112608320-A | Piperidine compound and preparation method and medical application thereof | 中国药科大学 | 2021-04-06 | — | — | CN | disclosed |
| CN-112533607-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2021047572-A1 | GSK-3β/CHE DOUBLE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2021-03-18 | — | — | WO | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2021043077-A1 | SUBSTITUTED PYRAZINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043077-A1 | SUBSTITUTED PYRAZINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-20210053982-A1 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-25 | — | — | US | disclosed |
| EP-3773569-A1 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | Nirogy Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112368283-A | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-108026094-B | Substituted 4-azaindoles and their use as modulators of the GLUN2B receptor | 詹森药业有限公司 | 2021-02-09 | — | — | CN | disclosed |
| WO-2021017068-A1 | PYRROLO-PYRAZOL DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海美迪西生物医药股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021022132-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | MAGNANI JOHN L (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-112261970-A | 3- (5-hydroxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family Zinc finger 2(IKZF2) dependent diseases | 诺华股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| WO-2021011435-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | MAGNANI JOHN L (US) | 2021-01-21 | — | — | WO | disclosed |
| CN-112236433-A | Novel compounds | 国家医疗保健研究所 | 2021-01-15 | — | — | CN | disclosed |
| EP-3762377-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | Cook, Timothy, H. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | LES LABORATOIRES SERVIER (FR) | 2020-12-31 | — | — | US | disclosed |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| US-20200399252-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| WO-2020255020-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020255020-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020245372-A1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020245372-A1 | HETEROCYCLIC IMMUNOMODULATORS AS PDL1 CHECKPOINT INHIBITOR | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-10 | — | — | WO | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| CN-112020500-A | Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase | 拉文纳制药公司 | 2020-12-01 | — | — | CN | disclosed |
| WO-2020228756-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020228756-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10829480-B2 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| WO-2020219417-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-3728228-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-106749268-B | Heteroaromatic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3717482-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Les Laboratoires Servier SAS (FR) | 2020-10-07 | — | — | EP | disclosed |
| US-10766882-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | YUNGJIN PHARM CO., LTD. (KR) | 2020-09-08 | — | — | US | disclosed |
| CN-109928967-B | Cyclized berberine derivative and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2020-09-04 | — | — | CN | disclosed |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| CN-111533721-A | Benzopyrone or quinolinone compounds and application thereof | 浙江大学 | 2020-08-14 | — | — | CN | disclosed |
| CN-111542524-A | Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 | 法国施维雅药厂 | 2020-08-14 | — | — | CN | disclosed |
| US-20200247824-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-08-06 | — | — | US | disclosed |
| CN-107428758-B | Acrylic acid derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-3684776-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | The University of Nottingham (GB) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
| CN-111423479-A | Compounds and methods for treating bacterial infections | 华盛顿大学 | 2020-07-17 | — | — | CN | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020139962-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20200199115-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| CN-108658716-B | Method for synthesizing olefin compound by photoinduction one-pot method | 清华大学 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020123435-A2 | METHODS OF TREATING HIV AND AIDS AND THE ELIMINATION OF LATENT RESERVOIRS OF HIV INFECTION USING SELECTIN, GALECTIN, AND SIGLEC ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| CN-111187172-A | Nitrophenyl ether compound, preparation method thereof, pharmaceutical composition and application | 中国药科大学 | 2020-05-22 | — | — | CN | disclosed |
| CN-108976227-B | Benzothiazine-4-ketone compound containing basic bridged ring segment and preparation method thereof | 浙江司太立制药股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20200148704-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3288938-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-20200140462-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
| EP-3383859-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-04-29 | — | — | EP | disclosed |
| US-10633375-B2 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | Jinagsu Hengrui Medicine Co., Ltd (CN) | 2020-04-28 | — | — | US | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-111051309-A | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
| CN-110993798-A | Perovskite type solar cell based on cooperative post-treatment of multiple ammonium salts and preparation method thereof | 北京大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-108659000-B | Heterocyclic compounds and process for preparing the same | 成都海创药业有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110914280-A | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triaza derivatives | 阿尤米制药公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3402784-B1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | disclosed |
| US-10577382-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-03 | — | — | US | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2020035058-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATING LIVER DISEASES AND APPLICATION THEREOF | 江苏新元素医药科技有限公司 | 2020-02-20 | — | — | WO | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-2968251-B1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARM INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| EP-3319963-B1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-08 | — | — | EP | disclosed |
| CN-110573509-A | MLKL inhibitors | 北京生命科学研究所 | 2019-12-13 | — | — | CN | disclosed |
| WO-2019234075-A1 | NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-12-12 | — | — | WO | disclosed |
| US-20190337957-A1 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-11-07 | — | — | US | disclosed |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | Basilea Pharmaceutica International AG (CH) | 2019-11-05 | — | — | US | disclosed |
| EP-2781519-B1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME | ST PHARM CO LTD (KR) | 2019-10-30 | — | — | EP | disclosed |
| CN-106061964-B | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders | 豪夫迈·罗氏有限公司 | 2019-10-25 | — | — | CN | disclosed |
| WO-2019191599-A1 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | SANDANAYAKA VINCENT (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191599-A1 | BICYCLIC ENONE CARBOXYLATES AS MODULATORS OF TRANSPORTERS AND USES THEREOF | SANDANAYAKA VINCENT (US) | 2019-10-03 | — | — | WO | disclosed |
| US-10428028-B2 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC | 2019-09-19 | — | — | US | disclosed |
| EP-2836539-B1 | MATERIALS COATED WITH CALIXARENES | UNIV LIBRE DE BRUXELLES ULB (BE) | 2019-09-18 | — | — | EP | disclosed |
| WO-2019173790-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | HLA TIMOTHY (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019170904-A1 | PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2019-09-12 | — | — | WO | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-13 | — | — | US | disclosed |
| US-20190233358-A1 | MATERIALS COATED WITH CALIXARENES | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2019-08-01 | — | — | US | disclosed |
| CN-105189524-B | The synthetic method of optical activity alpha-amino acid | 浜理药品工业株式会社 | 2019-07-19 | — | — | CN | disclosed |
| US-10350315-B2 | Quinoline-3-carboxamide compounds and their use in diagnosis | Westfaelische Wihelms-Universitaet Muenster (DE) | 2019-07-16 | — | — | US | disclosed |
| CN-110003169-A | GPR40 receptor agonist, method for preparing same, and pharmaceutical composition containing same as active ingredient | 株式会社LG化学 | 2019-07-12 | — | — | CN | disclosed |
| CN-109956942-A | Tryptamines ketones derivant and application thereof | 上海翔锦生物科技有限公司 | 2019-07-02 | — | — | CN | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10329232-B2 | Materials coated with calixarenes | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2019-06-25 | — | — | US | disclosed |
| CN-109928967-A | A kind of cyclisation berberinc derivate and its preparation method and application | 中国医学科学院医药生物技术研究所 | 2019-06-25 | — | — | CN | disclosed |
| US-20190185464-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-2805954-B1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| EP-2470499-B1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2019-06-12 | — | — | EP | disclosed |
| US-10301323-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| CN-109803651-A | Immunomodulator compounds | 凯莫森特里克斯股份有限公司 | 2019-05-24 | — | — | CN | disclosed |
| EP-3486242-A1 | OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-05-22 | — | — | EP | disclosed |
| US-10292394-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-21 | — | — | US | disclosed |
| US-20190106437-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-11 | — | — | US | disclosed |
| WO-2019067442-A1 | DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS | IDEAYA BIOSCIENCES, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| CN-109563094-A | Acyclic derivatives, their preparation method and the pharmaceutical composition containing them that new (miscellaneous) aryl replaces | 法国施维雅药厂 | 2019-04-02 | — | — | CN | disclosed |
| WO-2019058132-A1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-03-28 | — | — | WO | disclosed |
| CN-109476658-A | Substituted 5,6,7,8- tetrahydro [1,2,4] triazol [4,3-A] pyridine -3 (2H) -one and 2,5,6,7- tetrahydro -3H- pyrrolo- [2,1-c] [1,2,4] triazole -3- ketone and application thereof | 拜耳公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109415384-A | Condensed heterocyclic compouds | 武田药品工业株式会社 | 2019-03-01 | — | — | CN | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| US-20190008866-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3423435-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2019-01-09 | — | — | EP | disclosed |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| CN-108883099-A | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | 石全 | 2018-11-23 | — | — | CN | disclosed |
| CN-108884043-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-20180327392-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-11-15 | — | — | US | disclosed |
| EP-3131876-B1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3089970-B1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-108659000-A | Heterocyclic compound and preparation method thereof | 成都海创药业有限公司 | 2018-10-16 | — | — | CN | disclosed |
| US-20180291019-A1 | ACRYLIC ACID DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
| US-20180291006-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3097090-B1 | N-PHENYL-LACTAM DERIVATIVES CAPABLE OF STIMULATING NEUROGENESIS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-10-10 | — | — | EP | disclosed |
| EP-3383859-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | Mission Therapeutics Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| US-10085985-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3378861-A1 | ACRYLIC ACID DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2018-09-26 | — | — | EP | disclosed |
| CN-104487496-B | The material coated through calixarenes | 布鲁塞尔私立大学 | 2018-09-18 | — | — | CN | disclosed |
| CN-108495850-A | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2018-09-04 | — | — | CN | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
| CN-108430994-A | Compound, composition and method for adjusting CFTR | 蛋白质平衡治疗股份有限公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-108373468-A | A kind of preparation method of N-2- pyridines -5- pyrimetamines | 武汉工程大学 | 2018-08-07 | — | — | CN | disclosed |
| CN-108348529-A | HEPATITIS B CORE PROTEIN MODULATORS | 组装生物科学股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20180208606-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-20180208606-A1 | HISTONE DEACETYLASE INHIBITORS | REPLIGEN CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
| US-10029988-B2 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10029988-B2 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-07-24 | — | — | US | disclosed |
| CN-108290861-A | 1- cyano-pyrolidin derivatives as USP30 inhibitor | 特殊治疗有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-20180194792-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| EP-2799427-B1 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162823-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-14 | — | — | US | disclosed |
| US-9988379-B2 | GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG CHEM, LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| EP-2970139-B1 | HDAC INHIBITORS | BIOMARIN PHARM INC (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2945943-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2945943-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9975883-B2 | 1,2-naphthoquinone based derivative and method of preparing the same | YUNGJIN PHARM. CO., LTD. (KR) | 2018-05-22 | — | — | US | disclosed |
| EP-3319963-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| CN-108026094-A | Substituted 4-azaindoles and their use as modulators of the G L UN2B receptor | 詹森药业有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-9963447-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-08 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9957289-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110225-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-04-26 | — | — | US | disclosed |
| EP-3307725-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-04-18 | — | — | EP | disclosed |
| CN-107892689-A | One kind cyclisation berberinc derivate and its production and use | 中国医学科学院医药生物技术研究所 | 2018-04-10 | — | — | CN | disclosed |
| US-9926274-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3294726-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3288938-A1 | HERBICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-9908899-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908899-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| CN-107709314-A | Efflux pump inhibitor and its therapeutic use | 巴斯利尔药物国际股份公司 | 2018-02-16 | — | — | CN | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-3006449-B1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE ALPHA-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[C,E]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3274335-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-01-31 | — | — | EP | disclosed |
| US-20180016275-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2018-01-18 | — | — | US | disclosed |
| CN-107567455-A | Herbicidal compounds | 先正达参股股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| CN-104736535-B | Heterocyclic modulators of HIF activity for treatment of disease | 德州大学系统董事会 | 2017-12-19 | — | — | CN | disclosed |
| CN-104692413-B | A kind of method of NaY molecular sieve for preparing high silica alumina ratio and products thereof | 中国科学院大连化学物理研究所 | 2017-12-15 | — | — | CN | disclosed |
| EP-3252049-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252050-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2768822-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-12-06 | — | — | EP | disclosed |
| CN-107428758-A | Acrylic acid derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170333577-A1 | QUINOLINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE IN DIAGNOSIS | Westfälische Wilhelms-Universität Münster (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334865-A1 | DDR2 INHIBITORS AND METHODS OF USING | WASHINGTON UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9796687-B2 | S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2017-10-24 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CCHDI Foundation Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CCHDI Foundation Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| CN-107216286-A | The preparation method of the pyridinedicarboxylic acid dimethyl ester of 5 bromomethyl 2,3 | 江苏省农用激素工程技术研究中心有限公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-104870445-B | New dihydro-pyrimidin and isobioquin group and its pharmaceutical composition (GPR84 antagonists) for treating inflammatory disease | 加拉帕戈斯股份有限公司 | 2017-09-15 | — | — | CN | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170260221-A1 | Ruthenium-Based Photolinkers and Methods of Use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-09-14 | — | — | US | disclosed |
| CN-105209468-B | Substitution 7 Azabicyclic compounds and they as orexin receptor conditioning agent purposes | 詹森药业有限公司 | 2017-09-08 | — | — | CN | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253876-A1 | Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-09-07 | — | — | US | disclosed |
| EP-1904457-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3212636-A1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9732073-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732073-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| CN-105073741-B | Phthalazinones and isoquinolinones as ROCK inhibitors | 百时美施贵宝公司 | 2017-08-08 | — | — | CN | disclosed |
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3194382-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9714239-B2 | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders | HOFFMANN-LA ROCHE INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9708312-B2 | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists) | GALAPAGOS NV (BE) | 2017-07-18 | — | — | US | disclosed |
| US-20170197947-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| CN-106928247-A | Spiral shell oxindole compounds and its purposes as therapeutic agent | 泽农医药公司 | 2017-07-07 | — | — | CN | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9695112-B2 | Method for synthesizing optically active α-amino acid using chiral metal complex comprising axially chiral N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl] acetamide compound and amino acid | HAMARI CHEMICALS, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9682971-B2 | 1,2,5-Substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9682972-B2 | 1,2,5-substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| WO-2017093718-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| EP-2650283-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-2650282-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| CN-106749268-A | Heteroaryl compound and its application in medicine | 广东东阳光药业有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| CN-103664973-B | Spiro-oxindole compounds and their use as therapeutic agents | 泽农医药公司 | 2017-04-19 | — | — | CN | disclosed |
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017062581-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| CN-102256983-B | Spirooxindole compounds and their use as therapeutic agents | 泽农医药公司 | 2017-04-05 | — | — | CN | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-2935262-B1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3131876-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044186-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044186-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| WO-2017007938-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008890-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-12 | — | — | US | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016198691-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2016-12-15 | — | — | WO | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-9512143-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512143-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3097090-A1 | N-PHENYL-LACTAM DERIVATIVES CAPABLE OF STIMULATING NEUROGENESIS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | F. Hoffmann-La Roche AG (CH) | 2016-11-30 | — | — | EP | disclosed |
| US-20160340320-A1 | S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2016-11-24 | — | — | US | disclosed |
| EP-3095446-A1 | S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7 | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2016-11-23 | — | — | EP | disclosed |
| US-9499537-B2 | Antiviral pyrrolopyridine derivatives and method for preparing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-11-22 | — | — | US | disclosed |
| US-20160331749-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160326150-A1 | N-PHENYL-LACTAM DERIVATIVES CAPABLE OF STIMULATING NEUROGENESIS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3089970-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016174074-A1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-11-03 | — | — | WO | disclosed |
| CN-106061964-A | N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders | 豪夫迈·罗氏有限公司 | 2016-10-26 | — | — | CN | disclosed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-9458101-B2 | Colchicine derivatives, methods and uses thereof | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2016-10-04 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| WO-2016150971-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-09-29 | — | — | WO | disclosed |
| US-20160272600-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, LLC | 2016-09-22 | — | — | US | disclosed |
| US-20160272600-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, LLC | 2016-09-22 | — | — | US | disclosed |
| CN-105939996-A | Dihydropyridone and dihydropyridazinone derivatives as bromodomain inhibitors | 艾伯维公司 | 2016-09-14 | — | — | CN | disclosed |
| US-9428514-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-08-30 | — | — | US | disclosed |
| CN-103732597-B | Tricyclic heterocyclic compounds and JAK inhibitors | 日产化学工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| CN-105777623-A | Method for preparing pyridine side chain methyl quaternary ammonium compound | 北京颖泰嘉和生物科技股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2016-07-07 | — | — | US | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| CN-105682665-A | Compounds and methods for treating bacterial infections | 华盛顿大学 | 2016-06-15 | — | — | CN | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20160145289-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2016-05-26 | — | — | US | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| WO-2016066664-A1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| US-9328122-B2 | 7-substituted Hanfangichin B derivative, and preparation method and use thereof | HANGZHOU BENSHENG PHARMACEUTICALS CO., LTD. (CN) | 2016-05-03 | — | — | US | disclosed |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102045-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE a-AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL] ACETAMIDE COMPOUND AND AMINO ACID | HAMARI CHEMICALS, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102084-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102084-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| EP-3003322-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | Washington University (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006449-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE -AMINO ACID USING CHIRAL METAL COMPLEX COMPRISING AXIALLY CHIRAL N-(2-ACYLARYL)-2-[5,7-DIHYDRO-6H-DIBENZO[c,e]AZEPIN-6-YL]ACETAMIDE COMPOUND AND AMINO ACID | Hamari Chemicals, Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| WO-2016033440-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| CN-102791708-B | The inhibitor of AKT activity | ALMAC DISCOVERY LTD. (GB) | 2016-03-02 | — | — | CN | disclosed |
| EP-2321299-B1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9265770-B2 | 1,2,5-substituted benzimidazoles as FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20160046600-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | CHAI WENYING (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2401263-B1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-02-17 | — | — | EP | disclosed |
| US-20160039807-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2016-02-11 | — | — | US | disclosed |
| WO-2016022526-A1 | RUTHENIUM-BASED PHOTOLINKERS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022540-A1 | TRANSCRIPTOME IN VIVO ANALYSIS ( TIVA) AND TRANSCRIPTOME IN SITU ANALYSIS (TISA) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20160031823-A1 | HDAC INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031823-A1 | HDAC INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-02-04 | — | — | US | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248190-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248190-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2970099-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9212153-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| EP-2945943-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150329502-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| EP-2935262-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | Galapagos NV (BE) | 2015-10-28 | — | — | EP | disclosed |
| CN-105001226-A | Tricycle heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2015-10-28 | — | — | CN | disclosed |
| WO-2015160641-A2 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| US-20150291549-A1 | Compounds Useful as Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-15 | — | — | US | disclosed |
| US-20150291584-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG CHEM, LTD. (KR) | 2015-10-15 | — | — | US | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2917180-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG Life Sciences Ltd. (KR) | 2015-09-16 | — | — | EP | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150246052-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | US | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-1781629-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2015-07-29 | — | — | EP | disclosed |
| US-9090573-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2015108861-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015107053-A1 | N-PHENYL-LACTAM DERIVATIVES CAPABLE OF STIMULATING NEUROGENESIS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| US-9067917-B2 | 1,2,5-substituted benzimidazoles as FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2015089075-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2079722-B1 | SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONE AND 3-PHENYL-1-(PHENYLFURANYL)PROPAN-1-ONE DERIVATIVES, AND PREPARATION AND USE OF SAME | GENFIT (FR) | 2015-06-17 | — | — | EP | disclosed |
| US-20150158873-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158884-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARM INC (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158884-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARM INC (US) | 2015-06-11 | — | — | US | disclosed |
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2015079251-A1 | QUINAZOLINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-06-04 | — | — | WO | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| EP-2272973-B1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORP (US) | 2015-05-27 | — | — | EP | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9024027-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-05 | — | — | US | disclosed |
| US-9024027-B2 | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-05 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9000181-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2015-04-07 | — | — | US | disclosed |
| US-9000181-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2015-04-07 | — | — | US | disclosed |
| US-9000156-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| EP-2516445-B1 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150064455-A1 | MATERIALS COATED WITH CALIXARENES | UNIVERSITÉ PARIS CITÉ (FR) | 2015-03-05 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| EP-2836539-A1 | MATERIALS COATED WITH CALIXARENES | Université Libre de Bruxelles (ULB) (BE) | 2015-02-18 | — | — | EP | disclosed |
| US-8957066-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957066-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045367-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS LLC | 2015-02-12 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2627653-B1 | 3-AMINO-PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-8916580-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2014-12-23 | — | — | US | disclosed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| WO-2014194270-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140357647-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2014-12-04 | — | — | US | disclosed |
| EP-2805954-A1 | 7-SUBSTITUTED HANFANGICHIN B DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Hangzhou Bensheng Pharmaceutical Co., Ltd. (CN) | 2014-11-26 | — | — | EP | disclosed |
| EP-2801570-A1 | Inhibitors of beta-secretase | Vitae Pharmaceuticals, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883758-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2799427-A1 | Therapeutic compounds | Fibrotech Therapeutics PTY LTD (AU) | 2014-11-05 | — | — | EP | disclosed |
| EP-2797875-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | Pharmacyclics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2141149-B1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| CN-102112479-B | Buprenorphine analogs | PURDUE PHARMA L.P. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-20140314785-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140314785-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014164905-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| WO-2014151367-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2781519-A1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME | Korea Research Institute of Chemical Technology (KR) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014143666-A1 | HDAC INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2561872-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8828992-B2 | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-09 | — | — | US | disclosed |
| US-20140249162-A1 | NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVES AND METHOD FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-09-04 | — | — | US | disclosed |
| US-8815848-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815848-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1961733-B1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-08-20 | — | — | EP | disclosed |
| WO-2014113620-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113620-A2 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140200223-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2014-07-17 | — | — | US | disclosed |
| WO-2014109414-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2014-07-17 | — | — | WO | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8765757-B2 | 3-heterocyclic substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765812-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-07-01 | — | — | US | disclosed |
| WO-2014095798-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) | GALAPAGOS NV (BE) | 2014-06-26 | — | — | WO | disclosed |
| EP-2035369-B1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-06-25 | — | — | EP | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | disclosed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | disclosed |
| EP-2731942-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | Novartis AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| WO-2014073904-A1 | GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2014-05-15 | — | — | WO | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2509946-B1 | SPIRO INDOLE-CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-04-16 | — | — | EP | disclosed |
| CN-103732597-A | Tricyclic heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2014-04-16 | — | — | CN | disclosed |
| EP-2222660-B1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8674118-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014011010-A9 | METHOD FOR MANUFACTURING HYBRID ORGANIC/INORGANIC LIGHT-EMITTING DEVICE | 주식회사 동진쎄미켐 (KR) | 2014-03-06 | — | — | WO | disclosed |
| EP-2703404-A1 | Buprenorphine analogs | Purdue Pharma L.P. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-1824482-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8637549-B2 | Pyridons as PDK1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637549-B2 | Pyridons as PDK1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633212-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| CN-103450206-A | Buprenorphine analogs | PURDUE PHARMA LP | 2013-12-18 | — | — | CN | disclosed |
| EP-2326651-B1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA LP (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1910335-B1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-11-06 | — | — | EP | disclosed |
| WO-2013152967-A1 | MATERIALS COATED WITH CALIXARENES | UNIVERSITE LIBRE DE BRUXELLES (ULB) (BE) | 2013-10-17 | — | — | WO | disclosed |
| EP-2650283-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650282-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130259831-A1 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | disclosed |
| US-8530494-B2 | Buprenophine analogs | PURDUE PHARMA LP (US) | 2013-09-10 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2627650-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| WO-2013103724-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-8481517-B2 | Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-09 | — | — | US | disclosed |
| US-8481517-B2 | Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-09 | — | — | US | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101600-A1 | CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8 | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142807-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013072903-A1 | NITROIMIDAZOXADIAZOCINE COMPOUNDS | ITHEMBA PHARMACEUTICALS (PROPRIETARY) LIMITED (ZA) | 2013-05-23 | — | — | WO | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130102576-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-25 | — | — | US | disclosed |
| US-20130102576-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-04-25 | — | — | US | disclosed |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-8415365-B2 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415365-B2 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| EP-1879879-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2013-03-27 | — | — | EP | disclosed |
| US-8399472-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399472-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| EP-2546246-A2 | Compounds and methods for the treatment or prevention of flavivirus infections | Virochem Pharma Inc. (CA) | 2013-01-16 | — | — | EP | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2543664-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | Virochem Pharma Inc. (CA) | 2013-01-09 | — | — | EP | disclosed |
| US-8349814-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8329675-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| CN-102791708-A | Inhibitors of akt activity | ALMAC DISCOVERY LTD | 2012-11-21 | — | — | CN | disclosed |
| US-20120289522-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. | 2012-11-15 | — | — | US | disclosed |
| EP-2509946-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8287631-B2 | Compounds for preventing ghost odour | THOR GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8283361-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2012-10-09 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268858-B2 | e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection | PLEXXIKON INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8269044-B2 | Method for selectively producing primary amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8263608-B2 | Melanocortin receptor-specific spiro-piperidine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263608-B2 | Melanocortin receptor-specific spiro-piperidine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120225912-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2012-09-06 | — | — | US | disclosed |
| EP-2483252-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2114158-B1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012097196-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012097196-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2470499-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | Alberta Health Services (CA) | 2012-07-04 | — | — | EP | disclosed |
| CN-102532198-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC | 2012-07-04 | — | — | CN | disclosed |
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-06-28 | — | — | US | disclosed |
| EP-2241569-B1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | ZHEJIANG MED XINCHANG PHARM (CN) | 2012-05-23 | — | — | EP | disclosed |
| US-20120121541-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8178688-B2 | Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| WO-2012049555-A1 | SPIROCYCLIC COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2012-04-19 | — | — | WO | disclosed |
| US-8158675-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-04-17 | — | — | US | disclosed |
| WO-2012036974-A1 | NOVEL THIAZOL-CARBOXIMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2405917-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | Advinus Therapeutics Private Limited (IN) | 2012-01-18 | — | — | EP | disclosed |
| US-8097718-B2 | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| EP-2404607-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2401263-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK Biopharmaceuticals Co., Ltd. (KR) | 2012-01-04 | — | — | EP | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2398800-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399584-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2011-12-08 | — | — | US | disclosed |
| WO-2011149874-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | SCHERING CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149874-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | SCHERING CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275589-A1 | 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2383259-A1 | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-8026265-B2 | Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors | Istituto de Ricerche di Biologia Molecolare P. Angeletti SpA. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2361251-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361913-A1 | Anti-infective agents | Abbott Laboratories (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| EP-0853618-B1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2011095535-A2 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-11 | — | — | WO | disclosed |
| US-7994202-B2 | Bicyclic nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2011-07-07 | — | — | US | disclosed |
| CN-102112479-A | Buprenorphine analogs | PURDUE PHARMA LP | 2011-06-29 | — | — | CN | disclosed |
| EP-1979334-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011069298-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2011070039-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| CN-102099351-A | 3-heterocyclic substituted indole derivatives and methods of use thereof | SCHERING CORP | 2011-06-15 | — | — | CN | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20110136846-A1 | Buprenorphine Analogs | PURDUE PHARMA L.P. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2326651-A1 | BUPRENORPHINE ANALOGS | Purdue Pharma LP (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1581221-B1 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7943646-B2 | Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-05-17 | — | — | US | disclosed |
| EP-1585739-B1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | LILLY CO ELI (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2298767-A1 | NITROGENATED BICYCLIC HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902203-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011022805-A1 | NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF | ALBERTA HEALTH SERVICES (CA) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023812-A1 | MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS | NOVASAID AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| WO-2011014462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7875639-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-1560827-B1 | ANTI-INFECTIVE AGENTS | ABBOTT LAB (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010129467-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249098-A1 | OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249098-A1 | OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249402-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO. LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| US-20100240890-A1 | Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same | DONG WHA PHARMACEUTICAL IND. CO., LTD. | 2010-09-23 | — | — | US | disclosed |
| WO-2010103547-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234374-A1 | Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| WO-2010098600-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK HOLDINGS CO., LTD. (KR) | 2010-09-02 | — | — | WO | disclosed |
| EP-2222660-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216813-A1 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| WO-2010096722-A1 | 3-OXO-2, 3-DIHYDRO- [1,2, 4] TRIAZOLO [4, 3-A]PYRIDINES AS SOLUBLE EPOXIDE HYDROLASE (SEH) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010095767-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091104-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | EXELIXIS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100190745-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-07-29 | — | — | US | disclosed |
| US-20100186631-A1 | Compounds for preventing ghost odour | THOR GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100179172-A1 | N-PHENYL-METHANAMINE DERIVATIVE AND PESTICIDE CONTAINING IT | ISHIHARA SANGYO KAISHA , LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | PRENDERGAST GEORGE C | 2010-07-01 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-7705022-B2 | N-[2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(benzo[b]thiophen-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(indol-3-yl)ethyl]-S[(naphth-2-yl)methyl]-dithiocarbamate; anticarcinogenic agents; free of brassinin | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| EP-2170878-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING THE SAME | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172456-A1 | N-PHENYL-METHANAMINE DERIVATIVE AND PEST CONTROL AGENT CONTAINING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010037081-A1 | MELANOCORTIN RECEPTOR-SPECIFIC SPIRO-PIPERIDINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075966-A1 | Substituted Dihydroimidazoles and their Use in the Treatment of Tumors | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100041647-A1 | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2010014229-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029733-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010186-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| EP-2141149-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-20090281325-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2114158-A1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| US-7612097-B2 | Method for producing bactericidal pyridine compound and bactericidal pyridine compound | TAMA KAGAKU KOGYO CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2108017-A2 | IMIDAZOLONE COMPOUNDS AS TGF-BETA FAMILY TYPE I RECEPTORS, ALK5 AND/OR ALK4 ANTAGONISTS | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
| EP-1499672-B1 | METHOD FOR ATTACHMENT OF ONE OR MORE ORGANIC GROUPS ONTO A PARTICLE | CABOT CORP (US) | 2009-09-30 | — | — | EP | disclosed |
| EP-2099763-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-2081888-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| CN-101489564-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-7560544-B2 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1940787-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INST MEDICAL RES (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073816-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009079624-A1 | 4-IMIDAZOLIDINONES AS KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-2069327-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009064848-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009045313-A2 | OXYPIPERIDINE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-2035369-A1 | THERAPEUTIC COMPOUNDS | Fibrotech Therapeutics PTY LTD (AU) | 2009-03-18 | — | — | EP | disclosed |
| US-7504421-B2 | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504421-B2 | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-20090054642-A1 | NOVEL BENZAMIDINE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONGWHA PHARMACEUTICAL IND. CO., LTD. (KR) | 2009-02-26 | — | — | US | disclosed |
| WO-2009022185-A2 | 6, 6-FUSED HETEROCYCLES, THEIR PHARMACEUTICAL COMPOSITIONS AND METHOS OF USE | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A | 2009-02-12 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| WO-2009017346-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1581221-A4 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| EP-1505945-B1 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1979334-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong Wha Pharmaceutical. Ind. Co., Ltd. (KR) | 2008-10-15 | — | — | EP | disclosed |
| EP-1976834-A2 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973917-A2 | PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| EP-1966215-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| EP-1961733-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008099021-A1 | DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099021-A1 | DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1954133-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008094556-A2 | IMIDAZOLONE COMPOUNDS AS TGF-BETA FAMILY TYPE I RECEPTORS, ALK5 AND/OR ALK4 ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| WO-2008087367-A2 | SUBSTITUTED (PHENYLTHIAZOLYL)-PHENYL-PROPAN-1-ONE AND (PHENYLOXAZODYL)-PHENYL-PROPAN-1-ONE DERIVATIVES, PREPARATIONS AND USES OF SAME | GENFIT (FR) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008085505-A1 | 3-SUBSTITUTED-[1,2,3]BENZOTRIAZINONE COMPOUNDS FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940787-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | Lankenau Institute for Medical Research (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008080001-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910335-A1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1904477-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| CN-100376572-C | Anti-infective agents | ABBOTT LAB (US) | 2008-03-26 | — | — | CN | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008028937-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | NOVARTIS AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008022979-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1879879-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003141-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2008-01-10 | — | — | WO | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2007117404-A9 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIV VIRGINIA (US) | 2007-11-29 | — | — | WO | disclosed |
| US-7288623-B2 | Cyclic peptide tube | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2007117404-A2 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007089101-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL IND.CO., LTD. (KR) | 2007-08-09 | — | — | WO | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007072080-A2 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007065093-A2 | PYRROLIDINEANILINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | disclosed |
| EP-1781629-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007050963-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099961-A1 | Method for producing bactericidal pyridine compound and bactericidal pyridine compound | Kourai, Hiroki (JP) | 2007-05-03 | — | — | US | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007010144-A1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-12-07 | — | — | US | disclosed |
| EP-1505945-A4 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006119646-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
| US-7115591-B2 | Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-7109339-B2 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1683787-A1 | METHOD FOR PRODUCING BACTERICIDAL PYRIDINE COMPOUND AND BACTERICIDAL PYRIDINE COMPOUND | Tama Kagaku Kogyo Co., Ltd. (JP) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
| EP-1641765-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033796-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-7001895-B2 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LABORATORIES (US) | 2006-02-21 | — | — | US | disclosed |
| CN-1735612-A | Anti-infective agents | ABBOTT LAB (US) | 2006-02-15 | — | — | CN | disclosed |
| WO-2006014087-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) | 2006-02-09 | — | — | WO | disclosed |
| CN-1726042-A | Benzo[d]azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1581221-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6949545-B2 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005069750-A2 | THERAPEUTIC COMPOSITION WITH NANOSCALE ACTIVATION AGENTS | HEMOLYTICS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1505945-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6852158-B2 | Method for attachment of one or more organic groups onto a particle | CABOT CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1499672-A1 | METHOD FOR ATTACHMENT OF ONE OR MORE ORGANIC GROUPS ONTO A PARTICLE | CABOT CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108685-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1438313-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-07-21 | — | — | EP | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004056324-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-07-01 | — | — | US | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| CN-1500086-A | Aminopiperidine derivatives | 霍夫曼-拉罗奇有限公司 | 2004-05-26 | — | — | CN | disclosed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | disclosed |
| US-6737429-B2 | TREATMENT OF HIV MEDIATED DISEASES. | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040024176-A1 | Cyclic peptide tube | THE SCRIPPS RESEARCH INSTITUTE | 2004-02-05 | — | — | US | disclosed |
| US-20040007161-A1 | Method for attachment of one or more organic groups onto a particle | CABOT CORPORATION | 2004-01-15 | — | — | US | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003082968-A1 | METHOD FOR ATTACHMENT OF ONE OR MORE ORGANIC GROUPS ONTO A PARTICLE | CABOT CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-0723554-B1 | CYCLIC PEPTIDE TUBE | SCRIPPS RESEARCH INST (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1440385-A | Pyrrole derivatives for the treatment of AIDS | HOFFMANN LA ROCHE (CH) | 2003-09-03 | — | — | CN | disclosed |
| US-6613875-B1 | Cyclic peptide tube | THE SCRIPPS RESEARCH INSTITUTE | 2003-09-02 | — | — | US | disclosed |
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2003033502-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | disclosed |
| US-6544987-B2 | Pyrrolidine or piperidine sulfonyl compounds; stimulate neurite outgrowth in nerve cells leading to nerve regeneration for treatment of hair loss, memory loss or vision disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| US-6541276-B2 | Nucleophilic reaction of alkoxyamine | VERSICOR, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| EP-1265864-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1237869-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020061881-A1 | Compounds, compositions, and methods for stimulating neuronal growth and elongation | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1202968-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
| US-20010053555-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| WO-2001070691-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6281245-B1 | ADMINISTERING DEFORMYLASE INHIBITOR | VERSICOR, INC. | 2001-08-28 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001010834-A9 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2001-08-09 | — | — | WO | disclosed |
| EP-0806411-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0806410-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001040185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR STIMULATING NEURONAL GROWTH AND ELONGATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0806409-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0811599-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| US-6180816-B1 | COMPOUNDS WHICH ABROGATE HEMAGGLUTININ-MEDIATED FUSION OF VIRUS-HOST MEMBRANES; TREATING INFLUENZA | ELI LILLY AND COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6180815-B1 | COMPOUNDS WHICH ABROGATE HEMAGGLUTININ-MEDIATED FUSION OF VIRUS-HOST MEMBRANES; TREATING INFLUENZA | ELI LILLY AND COMPANY | 2001-01-30 | — | — | US | disclosed |
| US-6175034-B1 | Anti-viral compounds | ELI LILLY AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| EP-0806408-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6156924-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6127422-A | INHIBITING AN ENVELOPE VIRUS SELECTED FROM THE GROUP CONSISTING OF INFLUENZA BOVINE DIARRHEAL, HEPATITIS C AND TICK BORNE ENCEPHALITIS VIRUS THAT UNDERGOES HEMAGGLUTININ MEDIATED FUSION WITH A HOST CELL; PHENANTHRENE ESTERS | ELI LILLY AND COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| US-6124494-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6103922-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-6103923-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-6100426-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-08 | — | — | US | disclosed |
| US-6096917-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0664802-B1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0853618-A4 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999057097-A2 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES, AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5958918-A | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. | 1999-09-28 | — | — | US | disclosed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5872136-A | Arylheteroaryl inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0891361-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | disclosed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | disclosed |
| WO-1998018754-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES, AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0811600-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0811599-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997042155-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997041849-A1 | ANTI-VIRAL METHOD | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997041860-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997042156-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997041861-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997041822-A2 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997042154-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806203-A2 | Anti-viral compositions | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806411-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806410-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806409-A1 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806408-A1 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997036901-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5643906-A | LOWERING INTRAOCULAR PRESSURE FOR TREATMENT OF GLAUCOMA | G.D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| US-5602153-A | Method of using 1-arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of a giaucoma disorder | G.D. SEARLE & CO. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5563139-A | Method of using 1-arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0723554-A1 | CYCLIC PEPTIDE TUBE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0619819-B1 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0508445-B1 | 1-Arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1996-06-12 | — | — | EP | disclosed |
| US-5451593-A | Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451592-A | Angiotensin antagonist | C.D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451591-A | Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5441970-A | Administering angiotensin II antagonists to treat congestive heart failure or hypertension | G. D. SEARLE & CO. (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0664803-A1 | N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1995010535-A1 | CYCLIC PEPTIDE TUBE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0619819-A1 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS. | SEARLE & CO (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994008989-A1 | N-ARYLHETEROARYLALKYL 1-CYCLOALKYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994008990-A1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0579766-A1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-01-26 | — | — | EP | disclosed |
| US-5196537-A | Angiotensin/II/ antagonists; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| US-5164403-A | Hypotensive agents, cardiovascular disorders | G. D. SEARLE & CO. (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1992018092-A2 | 1-ARYLHETEROARYLALKYL SUBSTITUTED-1H-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508445-A1 | 1-Arylheteroarylalkyl substituted-1H-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5155117-A | Hypotensive agents | G. D. SEARLE & CO. (US) | 1992-10-13 | — | — | US | disclosed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0463054-A1 | SELECTIVE OXABICYCLOALKANES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-02 | — | — | EP | disclosed |
| WO-1990010634-A1 | SELECTIVE OXABICYCLOALKANES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-20 | — | — | WO | disclosed |
| EP-0388164-A1 | Selective oxabicycloalkanes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-19 | — | — | EP | disclosed |
| US-4332944-A | Compositions and use | ZOECON CORPORATION (US) | 1982-06-01 | — | — | US | disclosed |
| US-4018928-A | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-4018928-A | INHIBITORS OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |